News
Stay Up-To-Date on NEXT Oncology
- All
- NEXT Oncology Blog
- NEXT Oncology News
- Press Releases
NEXT Oncology and OncoBay Clinical Collaborate on Six Phase 1 Clinical Trials
FOR IMMEDIATE RELEASE DATE: April 22, 2024 Contact: Lisa Owens, 210-601-6647 (SAN ANTONIO, TX and RALEIGH, NC) April 22, 2024 ––NEXT Oncology, a Phase 1 Clinical Trial organization with six …
Announcing the 2024 Health Care Heroes
“We are so proud of our founder and CEO, Dr. Anthony Tolcher” for being named one of San Antonio’s Health Care Heroes by the San Antonio Business Journal. We will …
Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series
Biliary tract cancer (BTC) refers to several cancers of the biliary system, and covers a range of invasive adenocarcinomas, including intrahepatic cholangiocarcinoma (iCCA), extrahepatic cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma. …
D2M Biotherapeutics Announces First Patient Dosed in A Phase 1 Study Evaluating DM919, a Novel MICA/B Antibody for Treating Patients with Advanced Solid Tumors
D2M Biotherapeutics, Inc. (D2M), a clinical stage biotech company focused on developing innovative therapies in treating Immunological-Inflammatory diseases and cancers, today announced that the first patient had been dosed in …
Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate in a …
OnCusp Therapeutics Announces First Patient Dosed in Phase 1 Trial of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
NEW YORK, March 6, 2024 /PRNewswire/ — OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, today announced that …
Indapta Therapeutics Granted FDA Fast Track Designation for Natural Killer Cell Therapy for Hematologic Malignancies
Indapta Therapeutics has received FDA Fast Track Designation for its natural killer (NK) cell therapy IDP-023 for patients with multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). The company’s universal, allogeneic NK …
Indapta Therapeutics treats first subjects in Phase I cancer therapy trial
Indapta Therapeutics has commenced the Phase I clinical trial of natural killer (NK) cell therapy IDP-023, treating the first patients with multiple myeloma and non-Hodgkin’s lymphoma. Read full article
Natural Killer Cell Therapy to Be Studied in Blood Cancers
A phase 1 trial recently kicked off evaluating the novel drug, IDP-023 for the treatment of patients with relapsed or refractory multiple myeloma and non-Hodgkin lymphoma, according to a news …
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer …